| Name | Title | Contact Details |
|---|
Health In Tech is an insurtech company focused on enhancing the self-funding process in the healthcare sector. The company aims to create efficient and innovative solutions that benefit individuals and businesses while improving the health insurance landscape. It operates a dynamic marketplace that utilizes third-party AI technology to deliver customized solutions. The company offers a variety of proprietary digital platforms and services that streamline the quoting and underwriting processes for brokers, third-party administrators, and insurers. Key offerings include reference-based pricing, group insurance captives, community health plans, and the eDIYBS platform for small and medium-sized employers. Additionally, the Health Intelligence Card and HI Performance Network are designed to improve the management of medical records and claims while providing cost-effective healthcare options. Health In Tech, Inc. is publicly traded on NASDAQ under the ticker symbol HIT and was founded in 2014. The company is led by CEO Tim Johnson and has around 80 employees.
Small business banking and money management tools to put you in complete control of what your business is earning, spending and saving. The official banking platform of Profit First. Bank with Relay for: ✅ No fees or minimum balances that tie up cash flow ✅ Up to 20 checking accounts to organize income and expenses ✅ Spending management using 50 physical or virtual debit cards ✅ Payments and deposits via ACH transfers, checks and wires ✅ Secure, role-based access to team members and financial advisors ✅ Personalized customer support by email, phone or chat - Relay is a financial technology company, not a bank. Banking services and FDIC insurance are provided through Thread Bank; Member FDIC. The Relay Visa® Debit Card is issued by Thread Bank pursuant to a license from Visa U.S.A. Inc. and may be used everywhere Visa® debit cards are accepted.
Headquartered in Lyndhurst, NJ, NAVAC was incorporated in 2017 to enter the industrial vacuum market as a high quality and high performance alternative to the more expensive and recognizable name brands. With a vision of leading the global market in both industrial vacuum and HVAC/R tools (including vacuum pumps), and having already achieved the latter in 2002, NAVAC will take advantage of continuous technical innovation, superior customer service, and the ability to offer levels of customization not often seen in the industry to achieve the same result for industrial vacuum. NAVAC is committed to establishing long-term, mutually beneficial relationships with our partners by building fair and open platforms for cooperation. As such, we already have a strong OEM business in the U.S. as suppliers to some of the most well known brands in the world. We can offer the same levels of service and customization to our NAVAC end users as well. We currently offer a full line of one- and two-stage oil-sealed rotary vane vacuum pumps and accessories. NAVAC is Your Ideal Vacuum Pump no matter what the application and we are committed to winning your business. We offer a full line of high-quality, competitively priced pumps. Most all models are stocked in our NJ warehouse. If we do not offer what you are looking for as standard, we want to work with you to develop the perfect solution.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Acrisure Re is a leading re/insurance intermediary and corporate advisor/broker dealer, offering bespoke and innovative capital, risk, and program solutions. Our expert multi-disciplinary team leverage their combined experience, market data and leading analytics to provide the very best placement and execution strategies. Operating in Bermuda, Florida, Italy, London, Minnesota, New York, North Carolina, Seattle, Toronto and Zurich, our global team of experienced and talented employees are dedicated to driving a sophisticated, tech-enabled future for the (re)insurance industry.